Blood Reviews
Volume 22, Issue 3 , Pages 117-126 , May 2008

Management of viral hepatitis in hematologic malignancies

  • Roberto J. Firpi

      Affiliations

    • Assistant Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida Gainesville, FL
    • Corresponding Author InformationCorresponding author. Address: University of Florida, Section of Hepatobiliary Diseases, Department of Medicine, 1600 SW Archer Rd, P.O. Box 100214, JHMHC, Gainesville, Florida 32610-0214. Tel.: +352 392 7353; fax: +352 392 7393.
    • ,
  • David R. Nelson

      Affiliations

    • Associate Professor of Medicine & Chief Section of Hepatobiliary Diseases, Medical Director Liver Transplantation, Division of Gastroenterology, Hepatology and Nutrition University of Florida Gainesville, FL

References 

  1. Davis GL. Impact of HCV infection: Projections into the next century. 28[4], 390A. 1998. [abstract]. Hepatology 1998;28.
  2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745
  3. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173–S181
  4. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol. 2000;33:992–997
  5. Firpi RJ, Martin P. Update on hepatitis B treatment. MedGenMed. 2002;4:9
  6. de FR, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J.Hepatol. 2003;39 Suppl 1:S3-25.:S3–25.
  7. Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol. 2006;77:255–258
  8. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37:705–712
  9. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68
  10. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712
  11. Nagington J. Reactivation of hepatitis b after transplantation operations. Lancet. 1977;1:558–560
  12. Nordbo SA, Skaug K, Holter E, Waage A, Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol. 2000;65:86–87
  13. Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol. 2000;60:249–255
  14. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy–pathogenesis and management. Rev Med Virol. 2001;11:287–299
  15. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307
  16. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–220
  17. Zekri AR, Mohamed WS, Samra MA, et al. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol. 2004;13:305–311
  18. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925–929
  19. Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8 Suppl 1:107–109
  20. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–188
  21. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55–59
  22. Hui CK, Lie A, Au WY, et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood. 2005;106:464–469
  23. Maguire CM, Crawford DH, Hourigan LF, et al. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol. 1999;14:801–803
  24. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999;46:2925–2930
  25. Silvestri F, Sperotto A, Ermacora A, et al. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica. 2000;85:327–329
  26. Ustun C, Koc H, Karayalcin S, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:289–296
  27. Wong GC, Tan P, Goh YT, et al. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore. 1996;25:500–503
  28. Yagci M, Sucak GT, Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. Am J Hematol. 2000;64:233–234
  29. Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol. 1999;59:263–269
  30. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–709
  31. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2007;
  32. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–934
  33. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  34. Leung NW, Tam JS, Lau GT, et al. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer. 1994;73:1143–1148
  35. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–619
  36. Senecal D, Pichon E, Dubois F, et al. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant. 1999;24:1243–1244
  37. Dreger P, Rautenberg P, Kneba M, Schmitz N. Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC. Bone Marrow Transplant. 2000;26:114–116
  38. Iwai K, Tashima M, Itoh M, et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant. 2000;25:105–108
  39. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation. 1998;66:616–619
  40. Sekine R, Taketazu F, Kuroki M, et al. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int J Hematol. 2000;71:256–258
  41. McIvor C, Morton J, Bryant A, et al. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med. 1994;121:274–275
  42. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24:540–546
  43. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother. 2005;55:828–831
  44. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233–240
  45. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–1749
  46. Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320–1325
  47. Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88:209–215
  48. Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46:1049–1056
  49. Hsiao LT, Chiou TJ, Liu JH, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:84–94
  50. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172–180
  51. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722
  52. Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005;352:310–311
  53. Cortelezzi A, Vigano M, Zilioli VR, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35:467–469
  54. Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37:625–626
  55. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129:1198–1209
  56. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–2681
  57. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord. 2004;4:7–17
  58. Locasciulli A, Testa M, Valsecchi MG, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation. 1999;68:1486–1491
  59. Peffault dL, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–1624
  60. Ivantes CA, Amarante H, Ioshii SO, Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant. 2004;33:1181–1185
  61. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology. 1999;29:1893–1899
  62. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93:3259–3266
  63. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83:1224–1230
  64. Ribas A, Gale RP. Should people with hepatitis C virus infection receive a bone marrow transplant?. Bone Marrow Transplant. 1997;19:97–99
  65. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83:1998–2004
  66. Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol. 2003;25:184–192
  67. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2007;
  68. Peffault de LR, Asselah T, Levy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2005;36:709–713

PII: S0268-960X(08)00012-X

doi: 10.1016/j.blre.2008.02.001

Blood Reviews
Volume 22, Issue 3 , Pages 117-126 , May 2008

Article Tools

* Image Usage & Resolution